Mirum Pharmaceuticals Acquires Bluejay Therapeutics, Adding Brelovitug for HDV

Why It Matters

HDV has no approved therapies in the U.S., so brelovitug could become the first treatment, dramatically expanding Mirum’s market presence in a high‑mortality niche.

Key Takeaways

• Mirum adds brelovitug, Phase 3 HDV antibody, to pipeline
• AZURE Phase 3 data expected H2 2026, targeting 2027 launch
• FDA Breakthrough, EMA PRIME/Orphan designations support fast track
• $268.5 M financing backs development and commercial preparation
• Acquisition strengthens Mirum’s rare liver disease expertise

Pulse Analysis

Chronic hepatitis delta virus remains one of the most lethal forms of viral hepatitis, with limited therapeutic options and a mortality rate exceeding 50 % within a decade of diagnosis. Brelovitug’s mechanism—neutralizing both HDV and hepatitis B surface antigens—offers a dual‑action approach that could halt disease progression and reduce liver‑related complications. By targeting the viral envelope, the antibody aims to clear circulating virions while diminishing subviral particles that perpetuate immune activation, a strategy that differentiates it from nucleos(t)ide analogues used for HBV alone.

The regulatory landscape for brelovitug is unusually favorable. The FDA’s Breakthrough Therapy designation accelerates review timelines, while the European Medicines Agency’s PRIME and Orphan statuses provide incentives such as fee reductions and market exclusivity. Mirum’s recent $268.5 million private‑placement financing underscores investor confidence and supplies the capital needed for large‑scale Phase 3 execution, manufacturing scale‑up, and post‑approval preparedness. Integrating Bluejay’s scientific team into Mirum’s existing rare‑liver platform streamlines trial oversight and leverages established relationships with key opinion leaders and regulatory bodies.

If Phase 3 results meet expectations, brelovitug could launch as the first approved HDV therapy by 2027, opening a multi‑billion‑dollar market across the United States and Europe. Beyond revenue potential, the approval would validate antibody‑based interventions for viral hepatitis, encouraging further investment in biologics for other hard‑to‑treat viral diseases. Mirum’s expanded pipeline, now encompassing both HDV and its existing rare liver products, positions the company as a leading specialist capable of navigating the complex rare‑disease ecosystem and delivering high‑impact treatments to underserved patient populations.

Deal Summary

Mirum Pharmaceuticals completed its acquisition of Bluejay Therapeutics, adding the Phase 3 antibody brelovitug for chronic hepatitis delta virus (HDV) to its pipeline. The deal integrates Bluejay’s team and assets, aiming to finish the AZURE Phase 3 program and prepare for potential registration and launch in 2027. The acquisition was announced in a Jan 26, 2026 press release.